- 首页
- 关于我们
- 新闻中心
- 研发中心
- 产品介绍
抗体检测试剂
判断是否有供者特异性抗体(DSA)
详情>>
- 检测服务
- 技术支持
- 生物信息服务
摘要:This scoring system consistently classified patients into three categories of risk that predicted response to treatment within 28 days as well as risk of mortality from acute graft-versus-host disease.
资料分类:文献资料
上传时间:2018-02-06
资料下载:
摘要:The paper had compared 12 biomarkers in plasma obtained a median of 16 days after therapy initiation from patients with a complete response by day 28 after therapy initiation and in plasma obtained from patients with progressive GVHD during therapy. We found ST2 levels measured at the initiation of therapy for GVHD and during the first month after transplantation improved risk stratification for treatment-resistant GVHD and death without relapse after transplantation.
资料分类:文献资料
上传时间:2018-01-20
资料下载:
摘要:The paper had compared 8 biomarkers in plasma and found REG3α is a plasma biomarker of GI GVHD that can be combined with clinical stage and histologic grade to improve risk stratification of patients.
资料分类:文献资料
上传时间:2018-01-12
资料下载:
摘要:GenDx excellerator®、AlleleSEQR®、NGSgo®等系列产品获得CE认证。
资料分类:产品证书
上传时间:2018-01-04
资料下载:
摘要:HLA基因高分辨分型试剂(一代测序)
资料分类:使用说明
上传时间:2017-12-26
资料下载:
摘要:HLA基因高分辨分型试剂(一代测序,原雅培HLA分型试剂)
资料分类:使用说明
上传时间:2017-12-23
资料下载: